WebDoctor Encyclopedia

Carcinoma in situ

Lobular carcinoma in situ

Lobular carcinoma in situ (LCIS) is a risk marker rather than a true cancer. This entry covers classic versus pleomorphic LCIS and risk-reducing options.

Medically reviewed Last reviewed September 3, 2026

Overview

Lobular Carcinoma In Situ (LCIS) is a condition characterized by the presence of abnormal cells within the milk-producing glands (lobules) of the breast. Despite its name containing the word “carcinoma,” LCIS is not breast cancer. It is classified as a non-invasive neoplastic proliferation and, more importantly, a risk indicator (or “marker”) for the future development of invasive breast cancer in either breast.

Unlike Ductal Carcinoma In Situ (DCIS), which is considered a direct precursor (pre-cancer) to invasive ductal carcinoma, LCIS is generally not viewed as an obligate precursor that must be surgically excised to negative margins. Instead, it signals that the breast tissue environment is genetically unstable or hormonally responsive in a way that increases the lifetime probability of developing invasive carcinoma (either Invasive Lobular Carcinoma [ILC] or Invasive Ductal Carcinoma [IDC]).

A diagnosis of LCIS does not mean you have cancer. It means you have a higher-than-average risk of developing breast cancer in the future, warranting enhanced surveillance and risk-reduction discussions.

Epidemiology & Demographics

Feature Details
Incidence Increasing due to widespread screening mammography; estimated 2.5–4% of all breast biopsies.
Typical Age at Diagnosis Premenopausal women, peak incidence 40–50 years old. Rare in men.
Laterality Frequently bilateral (found in both breasts) at diagnosis (approx. 30–50%).
Multifocality Often multicentric (multiple distinct foci within the same breast).
Association Strongly associated with Hormone Receptor (ER/PR) positive biology.

Pathophysiology & Molecular Biology

LCIS originates from the terminal duct lobular unit (TDLU). The hallmark cellular change is the loss of function of the CDH1 gene (E-cadherin), a cell adhesion molecule. This loss results in discohesive cells that fail to stick together, leading to the characteristic “single-file” growth pattern seen in invasive lobular carcinoma, though in LCIS, the cells remain confined within the lobular basement membrane.

Molecular Subtypes:

  • Classic LCIS: Low to intermediate nuclear grade; ER+/PR+; HER2-.
  • Pleomorphic LCIS (PLCIS): Higher nuclear grade, central necrosis, HER2+ in a subset. Behaves more aggressively; often managed closer to DCIS (surgical excision recommended).
  • Florid LCIS: Extensive distension of acini involving numerous lobules; higher volume of disease.

How Does It Look? (Imaging & Gross/Microscopic Pathology)

Because LCIS rarely forms a distinct mass or calcifications, it is notoriously difficult to detect on imaging. It is most often an incidental finding on a biopsy performed for another reason (e.g., a nearby calcification, mass, or asymmetry).

1. Radiological Appearance (Mammography, Ultrasound, MRI)

Modality Typical Findings Sensitivity / Notes
Mammography (2D/3D Tomosynthesis) Usually occult (invisible).<br>• No specific findings in 70–90% of cases.<br>• Non-specific findings: Asymmetry, architectural distortion, or grouped non-calcified masses.<br>• Microcalcifications: Rarely produced by LCIS itself; if present, usually indicate co-existing DCIS. Low. Mammography is unreliable for diagnosing LCIS.
Ultrasound (US) Often negative.<br>• Non-specific hypoechoic area or subtle architectural distortion.<br>• No classic “mass” with angular margins. Low to Moderate. Useful for targeting biopsies of associated findings.
Breast MRI (Contrast-Enhanced) Most sensitive modality.<br>• Non-mass enhancement (NME) is the hallmark: <br> &nbsp;&nbsp;• Segmental or linear distribution.<br> &nbsp;&nbsp;• Internal enhancement: Heterogeneous, clumped, or stippled.<br>• Kinetic curve: Often persistent or plateau (Type 2/3). Moderate to High.<br>Used for staging extent of disease, contralateral screening, and monitoring response to chemoprevention.
Contrast-Enhanced Mammography (CEM) Emerging role; shows NME similar to MRI but with higher spatial resolution. Promising / Evolving.

Clinical Pearl: If a radiologist sees “Non-Mass Enhancement (NME) with segmental distribution”** on MRI, LCIS (and DCIS) are top differential diagnoses.

2. Gross Pathology (Macroscopic Appearance)

  • Classic LCIS: Grossly invisible. The tissue looks like normal breast parenchyma. No firmness, no gritty texture (unlike DCIS), no cysts.
  • Florid/Pleomorphic LCIS: Rarely, extensive involvement may cause palpable firmness or a subtle white-tan discoloration on cut section, but this is uncommon.

3. Microscopic Pathology (Histology)

This is the gold standard for diagnosis.

Feature Classic LCIS Pleomorphic LCIS (PLCIS) Florid LCIS
Architecture Distension of acini (acinar pattern) by a monotonous population of small, discohesive cells. Acini retain native shape. Similar distension but with marked nuclear pleomorphism and frequent central necrosis (comedo-type). Extensive involvement: >50% of lobules in a terminal duct lobular unit (TDLU) involved; often confluent.
Cell Morphology Small, round/oval nuclei; inconspicuous nucleoli; scant cytoplasm. Loss of polarity. Larger nuclei, high nuclear-to-cytoplasmic ratio, prominent nucleoli, mitotic figures. Similar to classic but sheer volume of involved lobules is high.
E-Cadherin (IHC) Negative (Loss of membranous staining). Diagnostic hallmark. Negative (usually). Negative.
p120 Catenin (IHC) Cytoplasmic staining (paranuclear dot-like). Confirms E-cadherin dysfunction. Cytoplasmic. Cytoplasmic.
ER / PR Strongly Positive (near 100%). Positive (usually). Positive.
HER2 Negative. Frequently Positive (Amplified/Over-expressed). Variable.
Ki-67 (Proliferation) Low (<5–10%). High (>20–30%). Variable/Intermediate.

Differential Diagnosis on Core Needle Biopsy:

  • vs. DCIS: DCIS cells are cohesive (E-cadherin +), often form solid/cribriform/papillary patterns, have basal myoepithelial cells intact.
  • vs. ALH (Atypical Lobular Hyperplasia): ALH involves partial distension of acini (<50% of acini in a TDLU) or insufficient number of involved acini. The distinction is quantitative/architectural.
  • vs. Invasive Lobular Carcinoma (ILC): ILC shows infiltration through basement membrane into stroma, desmoplastic reaction, “single file” infiltration of fat.

Symptoms

LCIS is asymptomatic in the vast majority of cases. It does not cause a palpable lump, pain, skin changes, or nipple discharge. It is a silent, microscopic diagnosis.

Clinical Presentation Scenarios

Scenario Frequency Description
Incidental Finding (Core Biopsy) >90% Biopsy performed for a suspicious imaging finding (calcifications, mass, asymmetry) nearby reveals LCIS in adjacent tissue. The target lesion may be benign, DCIS, or invasive cancer.
Incidental Finding (Excisional Biopsy) <10% Biopsy performed for a palpable lump or imaging finding reveals LCIS as the primary diagnosis (or co-existing with the target lesion).
Screening MRI Detection Increasing High-risk screening MRI identifies Non-Mass Enhancement (NME); biopsy confirms LCIS.
Risk-Reduction Surgery Specimen Rare Found prophylactically in mastectomy specimens for BRCA mutation carriers or strong family history.

Important: If you feel a lump, have nipple discharge, skin dimpling, or persistent focal pain, these symptoms are NOT caused by LCIS.** They require immediate evaluation to rule out invasive cancer or other pathology.

Diagnosis & Workup

1. The “Core Needle Biopsy Dilemma” (LCIS on Core Biopsy)

Finding LCIS on a percutaneous core needle biopsy (CNB) creates a management challenge: Is there something worse (DCIS or Invasive Cancer) nearby that the needle missed?

  • Concordance: Pathologist reviews imaging vs. pathology.
  • Concordant: Imaging finding (e.g., calcifications) explained by co-existing DCIS/ADH; LCIS is incidental. Management: Surveillance.
  • Discordant: Imaging finding (mass/asymmetry) not explained by LCIS (LCIS doesn’t make masses). Management: Surgical Excision mandatory to rule out invasion/DCIS.
  • Pleomorphic/Florid LCIS on Core: Generally recommend surgical excision due to higher upgrade rates (up to 20–30% to DCIS/Invasive) and difficulty assessing extent.
  • Classic LCIS on Core (Concordant/Incidental): Current guidelines (NCCN, ASCO, ESMO) support observation with enhanced surveillance without mandatory surgical excision, provided imaging-pathology concordance is confirmed.

2. Staging Workup (If LCIS is confirmed/isolated)

  • No systemic staging required (No CT, Bone Scan, PET/CT). LCIS is Stage 0 (Tis) but non-metastatic by definition.
  • Bilateral Breast MRI: Strongly recommended at diagnosis to assess extent of disease in the ipsilateral breast and screen the contralateral breast (high yield for occult contralateral LCIS/DCIS/Invasive cancer).
  • Genetic Counseling/Testing: Indicated if personal/family history meets criteria (e.g., NCCN guidelines). Note: LCIS alone is not an automatic indication for BRCA testing, but PLCIS may warrant panel testing.

Management & Treatment Options

Management is risk-adapted and shared decision-making is paramount.

1. Surgical Management

Approach Indication Details
Observation (No Surgery) Classic LCIS on core biopsy; Imaging-Pathology Concordant; Patient prefers surveillance. Standard of care per modern guidelines (NCCN, ASTRO/SSO). Requires strict adherence to surveillance.
Lumpectomy (Excisional Biopsy) Discordant imaging; Pleomorphic/Florid LCIS; Patient anxiety/preference; Positive margins on prior excision (if re-excision considered). Goal: Remove the imaging abnormality / confirm no invasion. Negative margins (no ink on tumor) are NOT required for classic LCIS (unlike DCIS). “Close” margins are acceptable.
Mastectomy (Unilateral/Bilateral) Diffuse/extensive LCIS (Florid) not amenable to lumpectomy; High-risk genetics (BRCA1/2, CDH1); Patient choice for maximal risk reduction. Contralateral Prophylactic Mastectomy (CPM): Discussed for risk reduction; does not improve survival compared to surveillance + chemoprevention, but reduces anxiety and future imaging burden.
Sentinel Lymph Node Biopsy (SLNB) Not routinely indicated for pure LCIS. Considered if: Mastectomy performed (cannot do SLNB later if invasion found), High suspicion of invasion on MRI, PLCIS with high-risk features.

2. Risk-Reducing Medication (Chemoprevention)

This is the most effective non-surgical intervention for LCIS. LCIS cells are ER+, making anti-estrogen therapy highly effective.

Agent Population Risk Reduction (Relative) Key Side Effects / Risks Duration
Tamoxifen (SERM) Pre & Postmenopausal ~50% reduction in invasive cancer risk (NSABP P-1, IBIS-I). Hot flashes, VTE (blood clots), Endometrial cancer (post-menopausal), Cataracts. 5 Years
Raloxifene (SERM) Postmenopausal only ~38–50% reduction (STAR trial). Lower VTE/Endometrial risk vs Tamoxifen. Hot flashes, leg cramps. 5 Years
Exemestane (AI) Postmenopausal only ~65% reduction (MAP.3 trial). Arthralgias, bone loss (osteoporosis), hot flashes, lipid changes. 5 Years
Anastrozole (AI) Postmenopausal only ~50% reduction (IBIS-II). Similar to Exemestane. 5 Years

Decision Aid: Use the Gail Model or Tyrer-Cuzick (IBIS) Model** (which incorporates LCIS) to calculate 5-year and lifetime risk. Discuss absolute risk reduction vs. side effect profile with a medical oncologist or breast specialist.

3. Enhanced Surveillance (The “Active Monitoring” Protocol)

If surgery is omitted or after excision, lifelong intensified screening is standard.

Modality Frequency Rationale
Clinical Breast Exam (CBE) Every 6–12 months Detect interval palpable changes.
Mammography (2D or 3D/Tomo) Annual Standard screening; detects DCIS/IDC (calcifications/masses).
Breast MRI (Contrast-Enhanced) Annual (staggered 6 months apart from Mammo) Gold standard for ILC detection. Detects non-mass enhancement (LCIS/ILC) missed on mammo.
Screening Schedule Example: Jan: MRI → July: Mammo → Jan: MRI… Alternating provides imaging every 6 months.

Prognosis & Long-Term Outlook

  • Survival: Excellent. LCIS itself is not life-threatening. Breast cancer-specific survival approaches 100% at 10–20 years.
  • Risk of Subsequent Invasive Cancer:
  • Annual risk: ~1–2% per year (cumulative ~15–20% at 15–20 years without intervention).
  • Laterality: Bilateral risk is equal. 50% of subsequent cancers occur in the contralateral (opposite) breast; 50% in the ipsilateral (same) breast.
  • Histology of Subsequent Cancer: ~50–60% are Invasive Lobular Carcinoma (ILC); ~30–40% are Invasive Ductal Carcinoma (IDC); rarely DCIS.
  • Impact of Chemoprevention: 5 years of Tamoxifen/AI reduces this cumulative risk by roughly 50%.
  • Impact of Bilateral Mastectomy: Reduces risk by >90–95%, but carries surgical morbidity and psychosocial impact.

Special Variants: Pleomorphic & Florid LCIS (PLCIS / FLCIS)

These represent a spectrum of “higher grade” lobular neoplasia.

Feature Clinical Significance
Pleomorphic LCIS (PLCIS) Higher nuclear grade, necrosis, often HER2+. Higher upgrade rate on excision (up to 30% invasive/DCIS). Managed more aggressively: Surgical excision to negative margins (>2mm often preferred) is standard. Chemoprevention still indicated.
Florid LCIS Extensive involvement of lobules. Higher volume disease. Excision recommended to assess extent/rule out invasion. If margins positive, re-excision often advised (unlike classic LCIS).
LCIS with Microinvasion Rare. Treated as Invasive Lobular Carcinoma (T1mi). Requires SLNB and standard invasive cancer workup.

Living with LCIS: Psychosocial & Practical Considerations

  1. Anxiety & “Cancer” Label: The word “Carcinoma” causes significant distress. Reframing: Clinicians should explicitly state: “This is a risk marker, not cancer. You do not need chemotherapy or radiation.”
  2. Insurance/Employment: In many jurisdictions, LCIS is coded as a “pre-existing condition” or “neoplasm of uncertain behavior” (ICD-10: D05.0). Verify coding with provider to avoid insurance denials for screening MRI (often requires high-risk codes like Z15.01 or Z80.3).
  3. Hormone Therapy (HT) for Menopause: Contraindicated. Systemic estrogen/progesterone therapy increases breast cancer risk in LCIS patients. Non-hormonal options (SSRIs/SNRIs, Gabapentin, Fezolinetant, lifestyle) are first-line for vasomotor symptoms.
  4. Oral Contraceptives (OCPs): Generally avoided (combined OCPs) due to estrogen component. Progestin-only methods (IUD, implant, mini-pill) are preferred if contraception needed.
  5. Fertility: Chemoprevention (Tamoxifen) is teratogenic (Category D). Effective non-hormonal contraception mandatory during treatment. Tamoxifen can induce ovulation; fertility preservation discussions needed pre-treatment if desired.
Aspect Classic LCIS Pleomorphic / Florid LCIS
Is it Cancer? No (Risk Marker / Stage 0) Borderline (Higher risk precursor)
Primary Treatment Surveillance + Chemoprevention Surgical Excision + Chemoprevention
Surgery Margins Not required (No ink on tumor) Negative margins preferred (>2mm)
Upgrade Rate (Core → Excision) Low (<5–10% for invasion/DCIS) Moderate/High (15–30%)
E-Cadherin Negative (Loss) Negative (Loss)
HER2 Status Negative Often Positive
Chemoprevention Benefit High (ER+) High (ER+), but biology more aggressive
Screening MRI Strongly Recommended (Annual) Strongly Recommended (Annual)
Contralateral Risk Equal to Ipsilateral Equal to Ipsilateral

Frequently Asked Questions (FAQ)

Q: “My biopsy says LCIS. Do I have cancer?”

A: No. LCIS is a collection of abnormal cells confined to the lobules. It cannot spread to lymph nodes or other organs. It is a risk factor, similar to having a strong family history or a BRCA mutation, but it is a tissue diagnosis.

Q: “Why did the radiologist miss it on my mammogram?”

A: LCIS rarely forms calcifications or a distinct mass. It looks like normal breast tissue on mammography and ultrasound. This is normal for this disease. MRI is the only test that reliably “sees” it, but even MRI misses some foci.

Q: “Do I need a mastectomy?”

A: Almost never required. Mastectomy is a personal choice for risk reduction, not a medical necessity for classic LCIS. Surveillance + medication offers equivalent survival outcomes with breast preservation.

Q: “If I take Tamoxifen, do I still need MRI screening?”

A: Yes. Chemoprevention reduces risk by ~50%, but does not eliminate it. MRI detects the cancers that do develop at the earliest, most curable stage.

Q: “Can men get LCIS?”

A: Extremely rare. Male breast tissue has rudimentary lobules. If diagnosed, management principles are similar, but data is limited to case reports.

Q: “Does LCIS turn into Invasive Lobular Carcinoma (ILC)?”

A: It can, but not inevitably. It is a “field defect”—the whole breast environment is primed for cancer. The subsequent cancer can be Lobular or Ductal, in either breast.

References

  • American College of Radiology. (2023) ACR Appropriateness Criteria®: Breast Cancer Screening. Reston, VA: American College of Radiology. Available at: https://acsearch.acr.org/list (Accessed: [Current Date]).
  • Arpino, G. et al. (2015) ‘Molecular taxonomy of breast cancer’, International Journal of Biological Markers, 30(4), pp. e394–e401.
  • Begossi, G. et al. (2018) ‘Lobular carcinoma in situ: A comprehensive review’, The Breast Journal, 24(6), pp. 927–934.
  • Cuzick, J. et al. (2013) ‘Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial’, The Lancet Oncology, 14(1), pp. 67–75.
  • Deeks, E.D. (2019) ‘Anastrozole: A Review in the Prevention of Breast Cancer’, Drugs, 79(14), pp. 1555–1565.
  • Goss, P.E. et al. (2011) ‘Exemestane for breast-cancer prevention in postmenopausal women’, New England Journal of Medicine, 364(25), pp. 2381–2391.
  • Hartmann, L.C. et al. (2017) ‘Benign breast disease and the risk of breast cancer’, New England Journal of Medicine, 372(2), pp. 178–187. (Classic NEJM review on LCIS/ALH risk).
  • Karnik, S. et al. (2020) ‘Pleomorphic lobular carcinoma in situ: A systematic review of the literature’, Annals of Surgical Oncology, 27(11), pp. 4228–4236.
  • King, T.A. et al. (2016) ‘Consensus guideline on the management of lobular carcinoma in situ’, Journal of Clinical Oncology, 34(10), pp. 1075–1082. (Joint SSO/ASTRO/ASCO Guideline).
  • Lacroix-Triki, M. et al. (2010) ‘E-cadherin gene mutation in lobular carcinoma in situ’, Journal of Pathology, 221(3), pp. 289–296.
  • National Comprehensive Cancer Network. (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer Risk Reduction, Version 1.2024. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf (Accessed: [Current Date]).
  • Page, D.L. et al. (2003) ‘Lobular carcinoma in situ: A 29-year follow-up’, Cancer, 98(8), pp. 1631–1636. (Landmark long-term natural history study).
  • Rakha, E.A. et al. (2018) ‘Invasive lobular carcinoma of the breast: morphology, biomarkers and genomics’, Histopathology, 72(1), pp. 66–80.
  • Sasco, A.J. et al. (1993) ‘Epidemiology of lobular carcinoma in situ of the breast’, European Journal of Cancer, 29A(12), pp. 1711–1715.
  • Virnig, B.A. et al. (2019) ‘Treatment patterns and outcomes for lobular carcinoma in situ’, Journal of the National Cancer Institute, 111(5), pp. 472–479.

Disclaimer